Jan Vesterbacka

About me
Publications
CV
Public outreach and news

About me

He is a Swedish-speaking Finn originally from Ostrobothnia, who moved to
Sweden and received the medical degree from Umeå Universitet in 1999. He
works as a MD specialist in Infectious Diseases since 2006. He joined group
Sönnerborg as a clinical collaborator in 2011, and got registered as a Ph.D.
student April 2014.
His research is focusing on microbial translocation during HIV-1 infection
with a special emphasis on elite controllers. We seek for the mechanism
behind this phenomenon. The aim of the project is to identify factors
contributing to the prolonged self-control of the virus in these subjects.
We will look at the distribution of immunological cells, and the expression
of their markers. We will also investigate the composition of the gut
microbiota in elite controllers and compare it with HIV-progressors` and
healthy controls` gut flora.

Articles

Article: AIDS REVIEWS. 2024;26(1):41-47
HTLV in Sweden
Vesterbacka J; Svensson A-K; Nowak P
Article: CELL HOST & MICROBE. 2024;32(2):156-161.e3
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: LIVER INTERNATIONAL. 2024;44(1):228-240
The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years
Kamal H; Lindahl K; Ingre M; Gahrton C; Karkkonen K; Nowak P; Vesterbacka J; Stal P; Wedemeyer H; Duberg A-S; Aleman S
Article: NPJ BIOFILMS AND MICROBIOMES. 2023;9(1):104
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren H-G; Buggert M; Manoharan L; Chen MS; Aleman S; Sonnerborg A; Nowak P
Article: EBIOMEDICINE. 2023;94:104700
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: AIDS. 2023;37(7):1023-1033
Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment
Svensson Akusjarvi S; Krishnan S; Ambikan AT; Mikaeloff F; Munusamy Ponnan S; Vesterbacka J; Lourda M; Nowak P; Sonnerborg A; Neogi U
Article: PLOS ONE. 2023;18(12):e0295838
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: IMMUNITY. 2022;55(9):1732-1746.e5
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: LIFE SCIENCE ALLIANCE. 2022;5(9):e202201405
Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection
Ambikan AT; Svensson-Akusjarvi S; Krishnan S; Sperk M; Nowak P; Vesterbacka J; Sonnerborg A; Benfeitas R; Neogi U
Article: HIV MEDICINE. 2022;23(8):895-910
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Anne AV; Oellinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K
Article: MOLECULAR MEDICINE. 2022;28(1):54
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Ballesteros OR; Muvva JR; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren H-G; Aleman S; Sandberg JK
Article: COMMUNICATIONS BIOLOGY. 2022;5(1):357
Peripheral blood CD4⁺CCR6⁺ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals
Svensson Akusjarvi S; Krishnan S; Jutte BB; Ambikan AT; Gupta S; Rodriguez JE; Vegvari A; Sperk M; Nowak P; Vesterbacka J; Svensson JP; Sonnerborg A; Neogi U
Article: ISCIENCE. 2022;25(1):103607
Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling
Akusjarvi SS; Ambikan AT; Krishnan S; Gupta S; Sperk M; Vegvari A; Mikaeloff F; Healy K; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: EBIOMEDICINE. 2021;74:103705
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: LANCET HIV. 2021;8(11):e711-e722
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
Bansi-Matharu L; Phillips A; Oprea C; Grabmeier-Pfistershammer K; Gunthard HF; De Wit S; Guaraldi G; Vehreschild JJ; Wit F; Law M; Wasmuth J-C; Chkhartishvili N; Monforte AD; Fontas E; Vesterbacka J; Miro JM; Castagna A; Stephan C; Llibre JM; Neesgaard B; Greenberg L; Smith C; Kirk O; Duvivier C; Dragovic G; Lundgren J; Dedes N; Knudsen A; Gallant J; Vannappagari V; Peters L; Elbirt D; Sarcletti M; Braun DL; Necsoi C; Mussini C; Muccini C; Bolokadze N; Hoy J; Mocroft A; Ryom L
Article: JOURNAL OF VIROLOGY. 2021;95(18):e0047921-10.1128/jvi.00421
Fecal Metabolome Signature in the HIV-1 Elite Control Phenotype: Enrichment of Dipeptides Acts as an HIV-1 Antagonist but a Prevotella Agonist
Sperk M; Ambikan AT; Ray S; Singh K; Mikaeloff F; Diez RC; Narayanan A; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: LAKARTIDNINGEN. 2021;118:21047
Tocilizumab bör övervägas i tidigt skede av svår covid-19.
Blennow O; Vesterbacka J; Nowak P
Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication
Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjarvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlen G; Asghar M; Sallberg M; Vesterbacka J; Nowak P; Vegvari A; Sonnerborg A; Treutiger CJ; Neogi U
Article: LAKARTIDNINGEN. 2020;117:20115
Tidiga erfarenheter av steroidbehandling vid covid-19.
Kan B; Ahl M; Blennow O; Eriksson P; Nowak P; Parke Å; Stojanovic B; Tovatt T; Vesterbacka J
Article: MEDICINE. 2018;97(12):e0162
Nonopportunistic infection leading to rapidly progressive dementia in a patient with HIV/AIDS A case report
Eimer J; Vesterbacka J; Savitcheva I; Press R; Roshanisefat H; Nowak P
Article: SCIENTIFIC REPORTS. 2017;7(1):6269
Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers
Vesterbacka J; Rivera J; Noyan K; Parera M; Neogi U; Calle M; Paredes R; Sonnerborg A; Noguera-Julian M; Nowak P
Article: INFECTIOUS DISEASES. 2016;48(6):449-452
Transition of HIV-infected youths from paediatric to adult care, a Swedish single-centre experience
Westling K; Naver L; Vesterbacka J; Belfrage E
Article: AIDS. 2015;29(18):2409-2418
Gut microbiota diversity predicts immune status in HIV-1 infection
Nowak P; Troseid M; Avershina E; Barqasho B; Neogi U; Holm K; Hov JR; Noyan K; Vesterbacka J; Svard J; Rudi K; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2015;31(8):830-836
Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy
Vesterbacka J; Barqasho B; Haggblom A; Nowak P
Article: LAKARTIDNINGEN. 2014;111(22-23):1002-1003
[From pediatric to adult clinic through a transition clinic. Experiences of HIV-infected young people who have been ill all their lives].
Westling K; Belfrage E; Navér L; Vesterbacka J
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(7):543-551
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
Andersson L-M; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sonnerborg A; Gisslen M
Article: PLOS ONE. 2013;8(1):e55038
Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
Vesterbacka J; Nowak P; Barqasho B; Abdurahman S; Nystrom J; Nilsson S; Funaoka H; Kanda T; Andersson L-M; Gisslen M; Sonnerborg A
Article: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2011;38(6):727-742
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients
Roshammar D; Simonsson USH; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslen M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(4):349-357
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na⟨ve HIV-1 infected patients
Josephson F; Andersson MCH; Flamholc L; Gisslen M; Hagberg L; Ormaasen V; Sonnerborg A; Vesterbacka J; Bottiger Y
Article: AIR MEDICAL JOURNAL. 2001;20(3):28-31
A rural ambulance helicopter system in northern Sweden.
Vesterbacka J; Eriksson A
Show more

All other publications

Letter: CLINICAL INFECTIOUS DISEASES. 2023;76(10):1864-1865
Successful Combination Treatment for Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Blennow O; Vesterbacka J; Tovatt T; Nowak P
Letter: JOURNAL OF INTERNAL MEDICINE. 2022;292(1):168-171
Incidence and severity of COVID-19 in adults with and without HIV diagnosis
Hedberg P; Vesterbacka J; Blennow O; Missailidis C; Nowak P; Naucler P
Letter: AIDS. 2022;36(3):479-481
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xu X; Vesterbacka J; Aleman S; Nowak P
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;289(3):434-436
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
Eimer J; Vesterbacka J; Svensson A-K; Stojanovic B; Wagrell C; Sonnerborg A; Nowak P
Thesis / dissertation: 2017
The role of microbial translocation and gut microbiota in HIV-1 infection
Vesterbacka, Jan

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2022-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2017

About me

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI